Barclays PLC Increases Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

Barclays PLC boosted its holdings in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) by 16.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 123,071 shares of the company’s stock after purchasing an additional 17,604 shares during the quarter. Barclays PLC owned approximately 0.24% of Spyre Therapeutics worth $2,866,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. F M Investments LLC acquired a new position in shares of Spyre Therapeutics during the 4th quarter worth approximately $1,136,000. Legal & General Group Plc raised its position in Spyre Therapeutics by 14.8% during the fourth quarter. Legal & General Group Plc now owns 37,490 shares of the company’s stock worth $873,000 after acquiring an additional 4,824 shares during the period. FMR LLC lifted its holdings in Spyre Therapeutics by 15.4% during the fourth quarter. FMR LLC now owns 8,801,266 shares of the company’s stock valued at $204,893,000 after purchasing an additional 1,177,385 shares in the last quarter. Wells Fargo & Company MN grew its position in shares of Spyre Therapeutics by 38.8% in the fourth quarter. Wells Fargo & Company MN now owns 24,718 shares of the company’s stock valued at $575,000 after purchasing an additional 6,908 shares during the period. Finally, ExodusPoint Capital Management LP increased its stake in shares of Spyre Therapeutics by 71.5% during the fourth quarter. ExodusPoint Capital Management LP now owns 16,691 shares of the company’s stock worth $389,000 after purchasing an additional 6,958 shares in the last quarter. 80.39% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Wolfe Research began coverage on Spyre Therapeutics in a report on Tuesday, March 18th. They issued an “outperform” rating and a $27.00 price objective on the stock. Leerink Partners began coverage on Spyre Therapeutics in a research report on Tuesday, April 8th. They set an “outperform” rating and a $45.00 price target for the company. The Goldman Sachs Group raised shares of Spyre Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 18th. Leerink Partnrs raised shares of Spyre Therapeutics to a “strong-buy” rating in a research note on Tuesday, April 8th. Finally, Wedbush restated an “outperform” rating and set a $65.00 target price on shares of Spyre Therapeutics in a report on Monday, January 13th. Eight investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $49.57.

Spyre Therapeutics Trading Up 2.4 %

Shares of NASDAQ SYRE opened at $15.02 on Wednesday. The stock has a fifty day simple moving average of $16.27 and a 200-day simple moving average of $23.08. Spyre Therapeutics, Inc. has a twelve month low of $10.91 and a twelve month high of $40.49. The stock has a market capitalization of $905.35 million, a PE ratio of -2.01 and a beta of 3.05.

Spyre Therapeutics (NASDAQ:SYRE) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.08. On average, equities analysts predict that Spyre Therapeutics, Inc. will post -4.46 earnings per share for the current year.

Spyre Therapeutics Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).